Delineating Toxicity Mechanisms Associated with MRI Contrast Enhancement through a Multidimensional Toxicogenomic Profiling of Gadolinium

2022 ◽  
Author(s):  
Roger M. Pallares ◽  
Dahlia D An ◽  
Solene Hebert ◽  
David Faulkner ◽  
Alex Loguinov ◽  
...  

Although gadolinium is widely used for magnetic resonance imaging in clinical settings, many concerns regarding its toxicity and bioaccumulation after gadolinium-based contrast agent (GBCA) administration have been raised and published...

2016 ◽  
Vol 7 (14) ◽  
pp. 2531-2541 ◽  
Author(s):  
Chunhua Guo ◽  
Ling Sun ◽  
Wenchuan She ◽  
Ning Li ◽  
Lei Jiang ◽  
...  

An amphiphilic dendronized heparin–gadolinium conjugate self-assembles into a nanoscale system by a combination of the features of the nanoparticle, dendrimer and heparin. The nanoscale system demonstrates great potential as an efficient and safe MRI contrast agent.


2021 ◽  
Vol 11 (17) ◽  
pp. 8222
Author(s):  
Shanti Marasini ◽  
Huan Yue ◽  
Adibehalsadat Ghazanfari ◽  
Son Long Ho ◽  
Ji Ae Park ◽  
...  

Surface-coating polymers contribute to nanoparticle-based magnetic resonance imaging (MRI) contrast agents because they can affect the relaxometric properties of the nanoparticles. In this study, polyaspartic acid (PASA)-coated ultrasmall Gd2O3 nanoparticles with an average particle diameter of 2.0 nm were synthesized using the one-pot polyol method. The synthesized nanoparticles exhibited r1 and r2 of 19.1 and = 53.7 s−1mM−1, respectively, (r1 and r2 are longitudinal and transverse water–proton spin relaxivities, respectively) at 3.0 T MR field, approximately 5 and 10 times higher than those of commercial Gd-chelate contrast agents, respectively. The T1 and T2 MR images could be obtained due to an appreciable r2/r1 ratio of 2.80, indicating their potential as a dual-modal T1 and T2 MRI contrast agent.


2020 ◽  
Author(s):  
Chen-ying Lu ◽  
Nan-Nan Zhang ◽  
Gao-feng Shu ◽  
Xiu-liang Zhu ◽  
Min-jiang Chen ◽  
...  

Abstract Background The development of sensitive and specific MRI contrast agents for early diagnosis of hepatocellular carcinoma is highly demanded. Here, a peptide A54 (sequence: AGKGTPSLETTP) functionalized superparamagnetic iron oxide nanoparticles (SPIONs)-based magnetic nanostructured lipid carrier(A54-MNLC)as a hepatoma targeting negative magnetic resonance imaging (MRI) contrast agent was developed. Results Firstly, the A54 peptide functionalized PEGylated SA (A54-PEG-SA) was synthesized by the coupling reaction between A54 and NH2-PEG-SA. Then SPIONs-loaded MNLC(MNLC and A54-MNLC)were prepared by the solvent diffusion method. The A54-MNLC with a diameter of about 50 nm, and in vitro cell viability study revealed that the prepared A54-MNLC was cytocompatible in the given particles’ concentration ranges. The cellular uptake results indicated that A54-MNLC was able to be uptaken specifically by human hepatoma cell line (Bel-7402 cells) and also can be used as efficient probe for targeted MR imaging of cancer cells in vitro. The in vivo MR imaging experiments using an orthotopic implantation model further validated the hepatoma-targeting ability of A54-MNLC with a more remarkable MR imaging contrast effect compared to MNLC. Conclusions These results demonstrate that the A54-MNLC is a promising nanoplatform as a targeted MR imaging contrast agent for the diagnosis of hepatocellular carcinoma.


2017 ◽  
Vol 8 (12) ◽  
pp. 8345-8350 ◽  
Author(s):  
Lina A. Basal ◽  
Matthew D. Bailey ◽  
Jonathan Romero ◽  
Meser M. Ali ◽  
Lyazat Kurenbekova ◽  
...  

Mechanistically unique 19F-EuII/III complex reports redox in vivo using both 1H- and 19F-MRI and displays temperature-dependent contrast enhancement.


2018 ◽  
Vol 59 (9) ◽  
pp. 1074-1081
Author(s):  
Dimitrios Mitsouras ◽  
Ming Tao ◽  
Margreet R de Vries ◽  
Kaspar Trocha ◽  
Oscar R Miranda ◽  
...  

Background Non-invasive monitoring of autologous vein graft (VG) bypass grafts is largely limited to detecting late luminal narrowing. Although magnetic resonance imaging (MRI) delineates vein graft intima, media, and adventitia, which may detect early failure, the scan time required to achieve sufficient resolution is at present impractical. Purpose To study VG visualization enhancement in vivo and delineate whether a covalently attached MRI contrast agent would enable quicker longitudinal imaging of the VG wall. Material and Methods Sixteen 12-week-old male C57BL/6J mice underwent carotid interposition vein grafting. The inferior vena cava of nine donor mice was treated with a gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA)-based contrast agent, with control VGs labeled with a vehicle. T1-weighted (T1W) MRI was performed serially at postoperative weeks 1, 4, 12, and 20. A portion of animals was sacrificed for histopathology following each imaging time point. Results MRI signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) were significantly higher for treated VGs in the first three time points (1.73 × higher SNR, P = 0.0006, and 5.83 × higher CNR at the first time point, P = 0.0006). However, MRI signal enhancement decreased consistently in the study period, to 1.29 × higher SNR and 2.64 × higher CNR, by the final time point. There were no apparent differences in graft morphometric analyses in Masson’s trichrome-stained sections. Conclusion A MRI contrast agent that binds covalently to the VG wall provides significant increase in T1W MRI signal with no observed adverse effects in a mouse model. Further optimization of the contrast agent to enhance its durability is required.


Sign in / Sign up

Export Citation Format

Share Document